These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 3555175)

  • 1. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A; Amor B; Menkès CJ; Weber S; Guérin F; Degeorges M
    Angiology; 1987 Apr; 38(4):333-7. PubMed ID: 3555175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A; Amor B; Menkès CJ
    Rev Rhum Mal Osteoartic; 1987 Jun; 54(6):487-90. PubMed ID: 3303287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nicardipine for the treatment of Raynaud's phenomena: a double blind crossover trial of a new calcium entry blocker.
    Rupp PA; Mellinger S; Kohler J; Dorsey JK; Furst DE
    J Rheumatol; 1987 Aug; 14(4):745-50. PubMed ID: 3312603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicardipine in the treatment of Raynaud's phenomenon. Dissociation of platelet activation from vasospasm.
    Wigley FM; Wise RA; Malamet R; Scott TE
    Arthritis Rheum; 1987 Mar; 30(3):281-6. PubMed ID: 2952125
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Hughes M; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2016 Feb; 2(2):CD002069. PubMed ID: 26914257
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Calcium channel blockers for primary Raynaud's phenomenon.
    Ennis H; Anderson ME; Wilkinson J; Herrick AL
    Cochrane Database Syst Rev; 2014 Jan; (1):CD002069. PubMed ID: 24482037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A; McCans J; Willan AR; Ford PM
    J Rheumatol; 1985 Aug; 12(4):724-7. PubMed ID: 3903157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Slow-releasing nicardipine in the treatment of Raynaud's phenomena without underlying diseases.
    Ferri C; Cecchetti R; Cini G; Gambini I; La Civita L; Bernini L; Bombardieri S; Pasero G
    Clin Rheumatol; 1992 Mar; 11(1):76-80. PubMed ID: 1582124
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised double-blind trial of diltiazem in the treatment of Raynaud's phenomenon.
    Kahan A; Amor B; Menkes CJ
    Ann Rheum Dis; 1985 Jan; 44(1):30-3. PubMed ID: 3882061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enalapril in Raynaud's phenomenon.
    Janini SD; Scott DG; Coppock JS; Bacon PA; Kendall MJ
    J Clin Pharm Ther; 1988 Apr; 13(2):145-50. PubMed ID: 2839529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Calcium antagonists for the treatment of Raynaud's phenomenon].
    Müller-Bühl U; Diehm C; Scheuermann W; Mörl H
    Dtsch Med Wochenschr; 1983 Nov; 108(47):1795-7. PubMed ID: 6357692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Controlled multicenter double-blind trial of nicardipine in the treatment of primary Raynaud phenomenon. French Cooperative Multicenter Group for Raynaud Phenomenon, Paris, France.
    Am Heart J; 1991 Jul; 122(1 Pt 2):352-5. PubMed ID: 2053556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of the calcium channel blocker nifedipine on Raynaud's phenomenon. A controlled double blind trial.
    Sauza J; Kraus A; González-Amaro R; Alarcón-Segovia D
    J Rheumatol; 1984 Jun; 11(3):362-4. PubMed ID: 6376801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind placebo-controlled crossover study of oral nicardipine in the treatment of Raynaud's phenomenon.
    Wollersheim H; Thien T
    J Cardiovasc Pharmacol; 1991 Dec; 18(6):813-8. PubMed ID: 1725892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravenous nicardipine in Raynaud's phenomenon: a controlled trial.
    van Heereveld H; Wollersheim H; Gough K; Thien T
    J Cardiovasc Pharmacol; 1988 Jan; 11(1):68-74. PubMed ID: 2450259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ketanserin in the treatment of Raynaud's phenomenon associated with generalized scleroderma.
    Engelhart M
    Br J Dermatol; 1988 Dec; 119(6):751-4. PubMed ID: 3060193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controlled trial of nifedipine in the treatment of Raynaud's phenomenon.
    Smith CD; McKendry RJ
    Lancet; 1982 Dec; 2(8311):1299-301. PubMed ID: 6128596
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Failure of a pure anti-platelet drug to decrease the number of attacks more than placebo in patients with Raynaud's phenomenon.
    Destors JM; Gauthier E; Lelong S; Boissel JP
    Angiology; 1986 Aug; 37(8):565-9. PubMed ID: 2943195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized double blind cross-over trial of nifedipine in the treatment of primary Raynaud's phenomenon.
    Corbin DO; Wood DA; Macintyre CC; Housley E
    Eur Heart J; 1986 Feb; 7(2):165-70. PubMed ID: 3516704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon.
    Rustin MH; Almond NE; Beacham JA; Brooks RJ; Jones DP; Cooke ED; Dowd PM
    Br J Dermatol; 1987 Dec; 117(6):751-8. PubMed ID: 3322358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.